137 related articles for article (PubMed ID: 15222121)
1. [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Hada M; Mizutari K
Gan To Kagaku Ryoho; 2004 Jun; 31(6):959-61. PubMed ID: 15222121
[TBL] [Abstract][Full Text] [Related]
2. [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Hada M; Horiuchi T; Shinji H
Gan To Kagaku Ryoho; 2006 Feb; 33(2):259-61. PubMed ID: 16484869
[TBL] [Abstract][Full Text] [Related]
3. [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Hada M; Mizutari K
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1407-10. PubMed ID: 15446566
[TBL] [Abstract][Full Text] [Related]
4. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Crane CH; Mason K; Janjan NA; Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Lipton A; Harvey H; Witters L; Kerr S; Legore K; Campbell C
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):43-5. PubMed ID: 15685834
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Dragovich T; Burris H; Loehrer P; Von Hoff DD; Chow S; Stratton S; Green S; Obregon Y; Alvarez I; Gordon M
Am J Clin Oncol; 2008 Apr; 31(2):157-62. PubMed ID: 18391600
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Tiberio GA; Nodari F; Strina C; Marini G
Cancer Chemother Pharmacol; 2006 Jan; 57(2):185-90. PubMed ID: 16151811
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
El-Rayes BF; Ali S; Sarkar FH; Philip PA
Mol Cancer Ther; 2004 Nov; 3(11):1421-6. PubMed ID: 15542781
[TBL] [Abstract][Full Text] [Related]
11. [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Xu G; Wu K; Wang XP; Zhao S
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):986-91. PubMed ID: 16060994
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Dickens DS; Cripe TP
J Pediatr Hematol Oncol; 2003 Sep; 25(9):709-14. PubMed ID: 12972806
[TBL] [Abstract][Full Text] [Related]
13. [A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Hada M; Horiuchi T
No Shinkei Geka; 2005 Oct; 33(10):1021-6. PubMed ID: 16223182
[TBL] [Abstract][Full Text] [Related]
14. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Cascinu S; Scartozzi M; Carbonari G; Pierantoni C; Verdecchia L; Mariani C; Squadroni M; Antognoli S; Silva RR; Giampieri R; Berardi R
Am J Clin Oncol; 2007 Oct; 30(5):526-30. PubMed ID: 17921715
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
Levitt RJ; Pollak M
Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Raut CP; Nawrocki S; Lashinger LM; Davis DW; Khanbolooki S; Xiong H; Ellis LM; McConkey DJ
Cancer Biol Ther; 2004 Dec; 3(12):1217-24. PubMed ID: 15477758
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Gately S; Kerbel R
Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
Shan YS; Lin PW
Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
[TBL] [Abstract][Full Text] [Related]
19. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
20. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Xiong HQ; Plunkett W; Wolff R; Du M; Lenzi R; Abbruzzese JL
Cancer Chemother Pharmacol; 2005 Jun; 55(6):559-64. PubMed ID: 15726370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
